AB1091 High acceptance rate in RA, as and PSA patients when being started on biosimilar TNF or being switched from the original TNF MAB (REMICADE, ENBREL) - a single center experience
Public health, health services research and health economics
AB1091 High acceptance rate in RA, as and PSA patients when being started on biosimilar TNF or being switched from the original TNF MAB (REMICADE, ENBREL) - a single center experience